Impact of receptor phenotype on nodal burden in patients with breast cancer who have undergone neoadjuvant chemotherapy
Authors
Boland, M. R.McVeigh, T. P.
O'Flaherty, N.
Gullo, G.
Keane, M.
Quinn, C. M.
McDermott, E. W.
Lowery, A. J.
Kerin, M. J.
Prichard, R. S.
Issue Date
2017-07-31Keywords
BREAST CANCERCHEMOTHERAPY
Metadata
Show full item recordCitation
Impact of receptor phenotype on nodal burden in patients with breast cancer who have undergone neoadjuvant chemotherapy 2017 BJS OpenPublisher
BSJ OpenJournal
BJS OpenDOI
10.1002/bjs5.6Additional Links
http://doi.wiley.com/10.1002/bjs5.6Abstract
Optimal evaluation and management of the axilla following neoadjuvant chemotherapy(NAC) in patients with node-positive breast cancer remains controversial. The aim of this study wasto examine the impact of receptor phenotype in patients with nodal metastases who undergo NAC to seewhether this approach can identify those who may be suitable for conservative axillary management.Methods: Between 2009 and 2014, all patients with breast cancer and biopsy-proven nodal diseasewho received NAC were identied from prospectively developed databases. Details of patients who hadaxillary lymph node dissection (ALND) following NAC were recorded and rates of pathological completeresponse (pCR) were evaluated for receptor phenotype.Item Type
ArticleLanguage
enISSN
24749842ae974a485f413a2113503eed53cd6c53
10.1002/bjs5.6